Nivolumab (Opdivo®) is licensed for the treatment of advanced renal cell carcinoma after prior therapy in adults.
Rapid Review
| Commenced | Completed | Outcome |
| 27/04/2016 | 16/05/2016 | Full Pharmacoeconomic Evaluation Recommended
|
Pharmacoeconomic Evaluation
| Commenced | Completed | Outcome |
| 28/10/2016 | 28/03/2017 | Reimbursement Not Recommended at the Submitted Price |
The HSE has approved reimbursement following confidential price negotiations October 2017.